KEYNOTE-522: Exploratory Analysis of EFS by Residual Cancer Burden With Neoadjuvant Pembrolizumab + Chemotherapy for Early TNBC

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Compared with placebo, pembrolizumab added to neoadjuvant chemotherapy was associated with lower residual cancer burden in patients with TNBC and with prolonged EFS even in patients without a pCR.
Format: Microsoft PowerPoint (.ppt)
File Size: 168 KB
Released: June 14, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings